Ingram, J. R., Porter, M., Chovatiya, R., Giamarellos-Bourboulis, E. J., Bechara, F. G., Fujita, H., Gulliver, W., Muller, E., Bari, M., Rolleri, R., Byerly, R., & Kirby, J. S. (2024). Bimekizumab Response Maintenance to 48 Weeks in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled Responder Analysis from the Phase 3, Double-Blind, Placebo-Controlled, Randomized Clinical Trials BE HEARD I and II. SKIN The Journal of Cutaneous Medicine, 8(2), s396. https://doi.org/10.25251/skin.8.supp.396